Table 3.

Nocturnal ventricular arrhythmias at baseline, and 3- and 12-month follow-up.

	Control		ASV		p -values
	N	Median [IQR] or n (%)	N	Median [IQR] or n (%)	Model 1	Model 2
Nocturnal ventricular arrhythmias, events per hour recording time
PVC/h at baseline	120	19.7 [3; 58]	119	29.1 [3; 95]	G: p = 0.413	G: p = 0.414
PVC/h at 3-month follow-up	79	19.0 [2; 63]	88	29.0 [2; 101]	T: p = 0.516	T: p = 0.482
PVC/h at 12-month follow-up	71	19.0 [5; 84]	70	26.0 [6; 118]	I: p = 0.800	I: p = 0.800
High burden of nocturnal ventricular arrhythmias, n, (%)
>30 PVC/h at baseline	120	47 (39)	119	58 (49)	G: p = 0.866	G: p = 0.883
>30 PVC/h at 3-month follow-up	79	31 (39)	88	41 (47)	T: p = 0.519	T: p = 0.550
>30 PVC/h at 12-month follow-up	71	29 (41)	70	30 (43)	I: p = 0.495	I: p = 0.511
Nocturnal high grade ventricular arrhythmias, n, (%)
≥1 NSVT at baseline	120	21 (18)	119	29 (24)	G: p = 0.473	G: p = 0.564
≥1 NSVT at 3-month follow-up	79	3 (25)	88	5 (16)	T: p = 0.860	T: p = 0.798
≥1 NSVT at 12-month follow-up	71	13 (18)	70	17 (24)	I: p = 0.095	I: p = 0.083

Data are expressed as median [interquartile range (IQR)] or number of patients (%). P-values (G, group; T, Time; I, Interaction Group

^*Time) correspond to linear mixed models based on ranks for the first endpoint and on generalized linear mixed models for the second and third endpoint.

Model 1: adjusted for baseline value of outcome variable; Model 2: adjusted for baseline value of outcome variable, left ventricular ejection fraction, intake of angiotensin converting enzyme inhibitors and β-receptor blockers.

ASV, adaptive servo-ventilation; NSVT, non-sustained ventricular tachycardia; PVC, premature ventricular complex.